CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Silence Therapeutics plc

SLN
$717MSmall Cap

Next catalyst

No upcoming catalyst in our data

No upcoming FDA decision, filing or trial readout is on file for SLN. That does not mean none is planned.

Get an email about SLN's next catalysts

Track Silence Therapeutics (SLN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Catalyst Timeline

0 upcoming, 2 past

No catalysts found.

How SLN's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈEuropeLONDON116 employees

Frequently asked questions

What is in Silence Therapeutics plc's drug pipeline?β†’

CatalystAlert tracks 5 drug candidates in Silence Therapeutics plc's (SLN) pipeline across Phase 2. Its lead program is Atu027 & gemcitabine in lead in safety period (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Silence Therapeutics plc's next FDA catalyst?β†’

CatalystAlert tracks every upcoming catalyst for Silence Therapeutics plc (SLN) β€” PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β€” each confidence-rated as confirmed, estimated or AI-detected.

How do I track SLN biotech catalysts?β†’

Add SLN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Silence Therapeutics plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply